Clinical trial · Observational
Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for CRC Screening
Subject Enrollment and Specimen Collection Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for Colorectal Cancer Screening
NCT04693546CI-TRIAL-00095877PREVENTsuspendedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): fundraising
Summary
Brief summary (as posted)
The purpose of this study is to determine the sensitivity and specificity for LifeKit Prevent Colorectal Neoplasia Test for colorectal cancer (CRC) and for adenoma, including advanced adenoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Adenoma | Colorectal Adenoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FIT Test | Diagnostic Test | — | UNRESOLVED |
| LifeKit Prevent Colorectal Neoplasia Test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Sensitivity and specificity for the LifeKit Prevent Colorectal Neoplasia Test for adenoma, including advanced adenoma
- timeFrame
- Through study completion, an average of 180 days
Secondary outcomes (4)
- measure
- Sensitivity and specificity of the LifeKit Prevent Colorectal Neoplasia Test for colorectal cancer
- timeFrame
- Through study completion, an average of 180 days
- measure
- Sensitivity and specificity of the LifeKit Prevent Colorectal Neoplasia Test for advanced adenoma
- timeFrame
- Through study completion, an average of 180 days
- measure
- Sensitivity of the LifeKit Prevent Colorectal Neoplasia Test is non-inferior to that of FIT for colorectal cancer
- timeFrame
- Through study completion, an average of 180 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: An individual must meet all of the criteria below to be eligible. 1. Subject is ≥ 40 years of age at the time of enrollment. 2. Subject presents for a screening colonoscopy per standard of care. 3. Subject has no symptoms or signs that require immediate, or near term, referral for diagnostic or therapeutic colonoscopy. 4. Subject is able and willing to sign informed consent. Exclusion Criteria: An individual meeting any of the below criteria is ineligible. 1. Subject has a history of CRC or advanced precancerous lesions. 2. Subject has a diagnosis or medical history of any of the following conditions: * Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome) * Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome") * Other hereditary cancer syndromes, including but are not limited to, Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis, or Familial Hyperplastic Polyposis 3. Subject has a diagnosis or personal history of inflammatory bowel disease (IBD), including chronic ulcerative colitis or Crohn's disease. 4. Subject has a diagnosis of Cronkhite-Canada Syndrome. 5. Subject has had a positive Cologuard, fecal occult blood test or FIT within the previous 2 years. 6. Subject has undergone a colonoscopy within the previous 9 years. 7. Subject has had overt rectal bleeding within the previous 30 days. 8. Subject has any condition that in the opinion of the Investigator should preclude participation in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.